Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment

BACKGROUND: Imatinib is the standard first-line therapy in metastatic gastrointestinal stromal tumours (GIST). Investigational multi-kinase inhibitors (MKIs) such as nilotinib, dasatinib or masitinib have been tested as first-line therapies in phase II/III studies. This might theoretically result ei...

Descripción completa

Detalles Bibliográficos
Autores principales: Boilève, Alice, Dufresne, Armelle, Chamseddine, Ali, Nassif, Elise, Dumont, Sarah, Brahmi, Medhi, Adam, Julien, Rouleau, Etienne, Karanian, Marie, Haddad, Véronique, Faron, Matthieu, Honoré, Charles, Meeus, Pierre, Le Cesne, Axel, Blay, Jean-Yves, Mir, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703411/
https://www.ncbi.nlm.nih.gov/pubmed/33246932
http://dx.doi.org/10.1136/esmoopen-2020-001082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703411/
https://www.ncbi.nlm.nih.gov/pubmed/33246932
http://dx.doi.org/10.1136/esmoopen-2020-001082

Ejemplares similares